CD45 + C1q + CCR8+ Cells as Emerging Indicators of Kidney Disease Severity and Progression Risk

Area of Science:

• Immunology
• Nephrology
• Biomarker Discovery

Background:

• Fibrosis is a key driver of organ failure, including kidney disease.
• Complement protein C1q and chemokine receptor 8 (CCR8) are implicated in fibrotic processes.
• CCL1 is the ligand for CCR8, suggesting a role in inflammatory pathways.

Purpose of the Study:

• To investigate the clinical significance of CD45+ mononuclear cells coexpressing C1q and CCR8 (CD45+C1q+CCR8+ cells) in patients with kidney disease.
• To determine if the percentage of these cells correlates with kidney function markers.
• To assess the association between CD45+C1q+CCR8+ cell levels and kidney disease progression.

Main Methods:

• Prospective observational study of 44 kidney disease patients.
• Flow cytometry was used to quantify peripheral blood CD45+C1q+CCR8+ cell percentages.
• Linear regression and Cox proportional hazards models analyzed correlations with clinical parameters and kidney outcomes.

Main Results:

• CD45+C1q+CCR8+ cell percentages positively correlated with serum creatinine and urinary protein levels.
• A higher percentage of these cells was associated with an increased risk of adverse kidney outcomes (end-stage kidney disease or 30% eGFR decline).
• Patients with moderately elevated percentages showed a significantly higher risk of kidney outcomes (HR: 27.31, p=0.04).

Conclusions:

• Peripheral blood CD45+C1q+CCR8+ cell percentages may serve as indicators of kidney function.
• These cells are associated with kidney disease progression, suggesting their potential as novel biomarkers.
• Further research could validate these findings for clinical application in managing kidney disease.